Amanda R Candelaria, RN | |
1 Fierro Ct, Los Lunas, NM 87031-5856 | |
(505) 903-9685 | |
Not Available |
Full Name | Amanda R Candelaria |
---|---|
Gender | Female |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 1 Fierro Ct, Los Lunas, New Mexico |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1326720707 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Amanda R Candelaria, RN 1 Fierro Ct, Los Lunas, NM 87031-5856 Ph: (505) 903-9685 | Amanda R Candelaria, RN 1 Fierro Ct, Los Lunas, NM 87031-5856 Ph: (505) 903-9685 |
News Archive
Cardiovascular leaders will gather in Minneapolis for a one-day summit on Jan. 20, to review data for Riata and Riata ST implantable cardioverter-defibrillator (ICD) leads, which recently underwent a Class I FDA recall. Physicians from the Minneapolis Heart Institute Foundation and Mayo Clinic have organized the summit to develop a consensus regarding the management of patients who have these leads.
The Valley Fever Center for Excellence at the University of Arizona College of Medicine - Tucson has been awarded a four-year, $4.8 million grant for research to speed development of a vaccine to combat Valley fever, the sometimes deadly respiratory illness caused by Coccidioides spores found in soils of the U.S. Southwest.
According to the new EU rules that came into force over the weekend, hundreds of herbal remedies are now banned. The laws are aimed at protecting consumers from potentially damaging "traditional" medicines.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.
› Verified 5 days ago